Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITCI Intra-Cellular Therapies	$131.87	$131.74	$64.09 ▼ $131.98	$14.05B	0.69	1.49 million shs	N/A
SMMT Summit Therapeutics	$24.61 -2.6%	$22.18	$2.10 ▼ $36.91	$18.28B	-0.94	3.85 million shs	2.04 million shs
TEVA Teva Pharmaceutical Industries	$17.48 -2.7%	$15.22	$12.47 ▼ $22.80	$19.82B	0.62	10.01 million shs	14.04 million shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$16.71 +2.8%	$17.06	$13.61 ▼ $30.36	$5.65B	N/A	27,461 shs	31,082 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+3.05%	+98.84%
SMMT Summit Therapeutics	-2.57%	+1.69%	+5.90%	+25.75%	+412.71%
TEVA Teva Pharmaceutical Industries	-2.43%	+8.35%	+30.21%	+7.04%	+3.62%
TLX Telix Pharmaceuticals Limited American Depositary Shares	+2.83%	-8.59%	+0.36%	-5.06%	+1,670,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITCI Intra-Cellular Therapies	0.6901 of 5 stars	1.1	0.0	0.0	4.5	0.6	1.7	0.6
SMMT Summit Therapeutics	2.9383 of 5 stars	4.5	1.0	0.0	0.0	4.0	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.5054 of 5 stars	3.6	5.0	0.8	0.0	3.9	0.8	0.6
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
SMMT Summit Therapeutics	3.09	Buy	$37.40	51.97% Upside
TEVA Teva Pharmaceutical Industries	3.13	Buy	$24.43	39.75% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	31.66% Upside

Current Analyst Ratings Breakdown

Latest TLX, TEVA, SMMT, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/23/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
3/26/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$35.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
SMMT Summit Therapeutics	$700K	26,110.01	N/A	N/A	$0.11 per share	223.73
TEVA Teva Pharmaceutical Industries	$16.62B	1.19	$3.46 per share	5.05	$4.75 per share	3.68
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.21	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.65	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	34.81	N/A	N/A	N/A	N/A	N/A

Latest TLX, TEVA, SMMT, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.78%	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Insider Ownership

Company	Insider Ownership
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	88.30%
TEVA Teva Pharmaceutical Industries	0.49%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.88 million	N/A	N/A

TLX, TEVA, SMMT, and ITCI Headlines

Recent News About These Companies

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025 | globenewswire.com

Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX

May 7, 2025 | accessnewswire.com

ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

May 6, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 5, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Still a Buy?

May 5, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?

May 4, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 2, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (TLX)

May 1, 2025 | nasdaq.com

TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation

May 1, 2025 | accessnewswire.com

What is William Blair's Estimate for TLX FY2026 Earnings?

May 1, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - What's Next?

April 30, 2025 | marketbeat.com

TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited

April 30, 2025 | accessnewswire.com

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

April 28, 2025 | globenewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud

April 28, 2025 | accessnewswire.com

Telix shares crash 8% on US FDA blow

April 27, 2025 | msn.com

Telix Pharmaceuticals Ltd. ADR

April 23, 2025 | wsj.com

Telix Reports US$186M Q1 Revenue, Up 62% YOY

April 22, 2025 | globenewswire.com

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

April 15, 2025 | globenewswire.com

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

April 14, 2025 | zacks.com

Telix Shares May Gain on the Distribution Deal With Cardinal Health

April 9, 2025 | zacks.com

Telix Announces Cardinal Health for Gozellix Commercial Distribution

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX, TEVA, SMMT, and ITCI Company Descriptions

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$24.61 -0.65 (-2.57%)

Closing price 05/13/2025 04:00 PM Eastern

Extended Trading

$24.85 +0.24 (+0.98%)

As of 08:07 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$17.48 -0.48 (-2.67%)

Closing price 05/13/2025 03:59 PM Eastern

Extended Trading

$17.51 +0.03 (+0.17%)

As of 08:06 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$16.71 +0.46 (+2.83%)

As of 05/13/2025 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time